Medically reviewed by Drugs.com. Last updated on Nov 13, 2022.
Applies to the following strengths: aooe 70 mg/mL; aooe 140 mg/mL
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Migraine Prophylaxis
70 mg subcutaneously once a month
- Some patients may benefit from 140 mg subcutaneously once a month
Use: For the preventative treatment of migraine.
Renal Dose Adjustments
No adjustment recommended
Liver Dose Adjustments
No adjustment recommended
Elderly: No specific recommendations, however, in general, dose selection should be cautious, generally starting at the low end of the dosing range.
- Serious hypersensitivity to the active substance or any product excipients; anaphylaxis and angioedema have occurred.
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Data not available
- For subcutaneous use only
- Administer subcutaneously in the abdomen, thigh, or upper arm; do not inject into areas where the skin is tender, bruised, red, or hard
- Patients/caregivers should be trained to properly administer using the single-dose prefilled autoinjector or single-dose prefilled syringe
- Store refrigerated at 2C to 8C (36F to 46F) in the original container to protect from light; do not freeze
- Once removed from refrigerator, keep at room temperature (up to 25C [77F]) in the original carton and use within 7 days; discard unused product kept at room temperature for more than 7 days
- Prior to administration, allow drug to sit at room temperature for at least 30 minutes (protect from direct sunlight); do not warm by using a heat source such as hot water or a microwave
- Do not shake
- The needle shield within the white cap of the prefilled autoinjector and gray needle cap of the prefilled syringe contain dry natural rubber (a derivative of latex); this may cause allergic reactions in individuals sensitive to latex.
- In clinical trials, doses of 70 mg and 140 mg were compared to placebo; drug-treatment with both doses demonstrated statistically significant improvements compared to placebo; additionally, patients receiving 140 mg/month showed some improvement over the 70 mg/month dose, although doses were not titrated up nor directly compared.
- Monitor for severe constipation
- Monitor for hypertension
- Patients should be instructed to read the US FDA-approved Patient Information and Instructions for Use.
- Patients should receive instruction on proper subcutaneous administration technique.
- Patients should be instructed to seek immediate medical attention if they experience any symptoms of a serious or severe hypersensitivity reaction, severe constipation, and/or hypertension or worsening of preexisting hypertension.
Frequently asked questions
- What are the new drugs for the treatment of migraines?
- Ajovy vs Aimovig: What's the difference between them?
- Why does Aimovig cause constipation?
- How long does Aimovig last in your system?
- What is the mechanism of action of Aimovig?
- Can you drink alcohol with Aimovig?
- Can Aimovig cause hair loss (alopecia)?
- How do you use the Aimovig autoinjector?
- Emgality vs Aimovig - how do they compare?
More about erenumab
- Check interactions
- Compare alternatives
- Reviews (614)
- Side effects
- During pregnancy
- Support group
- Drug class: CGRP inhibitors
- En español
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.